Reproductive Capacity & Iron Burden in Thalassemia

Status Completed

Clinical Trial Summary

The improved long-term survival of thalassemia major (TM) patients has resulted in increased focus on the ability to preserve fertility. While the association of iron toxicity with vital organ dysfunction, heart and liver, has been extensively investigated, the correlation of reproductive capacity and extent of iron overload is not well understood. Despite remarkable progress in methodology for prediction of reproductive status and intervention for preserving fertility, implementation in thalassemia is lacking. The investigators hypothesize that iron toxicity to the anterior pituitary occurring in the process of transfusional iron loading is directly associated with a decline in gonadal function. The investigators expect pituitary MRI measurements of iron deposition as well as markers of oxidative damage to correlate with the functional studies of pituitary-gonadal axis performed in this study. This cross sectional study will examine the relation of pituitary iron deposition and pituitary volume; serum iron and oxidative stress measures, liver iron concentration (LIC), cardiac iron and chelation adequacy with pituitary and gonadal reproductive hormone levels (and spermatogenesis in adult male patients), in order to better define the association of iron burden and chelation patterns with fertility potential, in thalassemia patients with iron overload. The study will assess whether the current chelation treatment regimens, in particular during the pubertal developmental age, are adequate for preserving fertility and could lead to improved chelation routines for preventing the high prevalence of compromised fertility. In addition, by utilizing state-of-the-art markers for fertility status, findings from this study may improve current methods for screening for hypogonadism and reproductive potential and allow earlier intervention. The investigators propose to examine 26-30 patients, 12 years and older, with measures of fertility potential, and correlate them to their current iron burden parameters and to the cumulative iron effect as indicated by past iron overload patterns and chelation history.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02308904
Study type	Interventional
Source	UCSF Benioff Children's Hospital Oakland
Contact
Status	Completed
Phase	N/A
Start date	June 1, 2013
Completion date	September 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02559648` - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis	Phase 2
Recruiting	`NCT02126046` - Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major	N/A
Completed	`NCT01125254` - Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major	Phase 2/Phase 3
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Completed	`NCT00733811` - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP	Phase 4
Enrolling by invitation	`NCT02986698` - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)	Phase 1
Not yet recruiting	`NCT06026839` - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Terminated	`NCT00007072` - Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major	Phase 2
Completed	`NCT04292314` - Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia	Phase 2/Phase 3
Completed	`NCT02049450` - Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.	Phase 2
Active, not recruiting	`NCT04523376` - Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies	N/A
Completed	`NCT03992001` - Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients	Phase 4
Not yet recruiting	`NCT05777733` - NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major	Phase 1
Completed	`NCT01241357` - High-Tc Susceptometer to Monitor Transfusional Iron Overload	Phase 2
Completed	`NCT00749515` - Pilot Study for Patients With Poor Response to Deferasirox	Phase 4
Completed	`NCT04260516` - The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major	Phase 1
Recruiting	`NCT02307786` - Long Term Outcomes in β Thalassemia Major	N/A
Not yet recruiting	`NCT01323608` - The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study	Phase 4
Completed	`NCT00005893` - Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders	N/A
Recruiting	`NCT06137079` - "Iron Overload and Endocrinological Diseases"

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Reproductive Capacity and Iron Burden in Thalassemia — Fertility thal

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms